Trials / Unknown
UnknownNCT05744674
Phase Ⅱ Study of Intercostal Nerve Block With HR18034 for Postsurgical Pain Management
A Phase Ⅱ Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Single Injection Intercostal Nerve Block With HR18034 for Postoperative Pain Management
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase Ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection intercostal nerve block with HR18034 for postoperative pain management compared with ropivacaine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HR18034 | HR18034 228mg/342mg/456mg |
| DRUG | Ropivacaine Hydrochloride Injection | Ropivacaine Hydrochloride Injection 60mg/90mg/120mg |
Timeline
- Start date
- 2023-02-21
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
- First posted
- 2023-02-27
- Last updated
- 2023-03-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05744674. Inclusion in this directory is not an endorsement.